DP00390: Beta-arrestin-1 [Isoform 1A]FASTA viewXML view

General information
DisProt:DP00390
Name:Beta-arrestin-1 [Isoform 1A]
Synonym(s):ARRB1_BOVIN
Arrestin beta-1
Arrestin-2
First appeared in release:Release 3.0 (02/17/2006)
UniProt:P17870-1
UniGene:Bt.52082
SwissProt: ARRB1_BOVIN
TrEMBL:  
NCBI (GI): 114210
Source organism:Bos taurus (Bovine)
Sequence length:418
Percent disordered:17%
Homologues: 


Native sequence

        10         20         30         40         50         60
         |          |          |          |          |          |
MGDKGTRVFK KASPNGKLTV YLGKRDFVDH IDLVEPVDGV VLVDPEYLKE RRVYVTLTCA - 60
FRYGREDLDV LGLTFRKDLF VANVQSFPPA PEDKKPLTRL QERLIKKLGE HAYPFTFEIP - 120
PNLPCSVTLQ PGPEDTGKAC GVDYEVKAFC AENLEEKIHK RNSVRLVIRK VQYAPERPGP - 180
QPTAETTRQF LMSDKPLHLE ASLDKEIYYH GEPISVNVHV TNNTNKTVKK IKISVRQYAD - 240
ICLFNTAQYK CPVAMEEADD TVAPSSTFCK VYTLTPFLAN NREKRGLALD GKLKHEDTNL - 300
ASSTLLREGA NREILGIIVS YKVKVKLVVS RGGLLGDLAS SDVAVELPFT LMHPKPKEEP - 360
PHREVPEHET PVDTNLIELD TNDDDIVFED FARQRLKGMK DDKEEEEDGT GSPRLNDR



Functional narrative    

Functions in regulating agonist-mediated G-protein coupled receptor (GPCR) signaling by mediating both receptor desensitization and resensitization processes. During homologous desensitization, beta-arrestins bind to the GPRK-phosphorylated receptor and sterically preclude its coupling to the cognate G-protein; the binding appears to require additional receptor determinants exposed only in the active receptor conformation. The beta-arrestins target many receptors for internalization by acting as endocytic adapters (CLASPs, clathrin-associated sorting proteins) and recruiting the GPRCs to the adaptor protein 2 complex 2 (AP-2) in clathrin-coated pits (CCPs). However, the extent of beta-arrestin involvement appears to vary significantly depending on the receptor, agonist and cell type. Internalized arrestin-receptor complexes traffic to intracellular endosomes, where they remain uncoupled from G-proteins. Two different modes of arrestin-mediated internalization occur. Class A receptors, like ADRB2, OPRM1, ENDRA, D1AR and ADRA1B dissociate from beta-arrestin at or near the plasma membrane and undergo rapid recycling. Class B receptors, like AVPR2, AGTR1, NTSR1, TRHR and TACR1 internalize as a complex with arrestin and traffic with it to endosomal vesicles, presumably as desensitized receptors, for extended periods of time. Receptor resensitization then requires that receptor-bound arrestin is removed so that the receptor can be dephosphorylated and returned to the plasma membrane. Involved in internalization of P2RY4 and UTP-stimulated internalization of P2RY2. Involved in phopshorylation-dependent internalization of OPRD1 ands subsequent recycling. Involved in the degradation of cAMP by recruiting cAMP phosphodiesterases to ligand-activated receptors. Beta-arrestins function as multivalent adapter proteins that can switch the GPCR from a G-protein signaling mode that transmits short-lived signals from the plasma membrane via small molecule second messengers and ion channels to a beta-arrestin signaling mode that transmits a distinct set of signals that are initiated as the receptor internalizes and transits the intracellular compartment. Acts as signaling scaffold for MAPK pathways such as MAPK1/3 (ERK1/2). ERK1/2 activated by the beta-arrestin scaffold is largely excluded from the nucleus and confined to cytoplasmic locations such as endocytic vesicles, also called beta-arrestin signalosomes. Recruits c-Src/SRC to ADRB2 resulting in ERK activation. GPCRs for which the beta-arrestin-mediated signaling relies on both ARRB1 and ARRB2 (codependent regulation) include ADRB2, F2RL1 and PTH1R. For some GPCRs the beta-arrestin-mediated signaling relies on either ARRB1 or ARRB2 and is inhibited by the other respective beta-arrestin form (reciprocal regulation). Inhibits ERK1/2 signaling in AGTR1- and AVPR2-mediated activation (reciprocal regulation). Is required for SP-stimulated endocytosis of NK1R and recruits c-Src/SRC to internalized NK1R resulting in ERK1/2 activation, which is required for the antiapoptotic effects of SP. Is involved in proteinase-activated F2RL1-mediated ERK activity. Acts as signaling scaffold for the AKT1 pathway. Is involved in alpha-thrombin-stimulated AKT1 signaling. Is involved in IGF1-stimulated AKT1 signaling leading to increased protection from apoptosis. Involved in activation of the p38 MAPK signaling pathway and in actin bundle formation. Involved in F2RL1-mediated cytoskeletal rearrangement and chemotaxis. Involved in AGTR1-mediated stress fiber formation by acting together with GNAQ to activate RHOA. Appears to function as signaling scaffold involved in regulation of MIP-1-beta-stimulated CCR5-dependent chemotaxis. Involved in attenuation of NF-kappa-B-dependent transcription in response to GPCR or cytokine stimulation by interacting with and stabilizing CHUK. May serve as nuclear messenger for GPCRs. Involved in OPRD1-stimulated transcriptional regulation by translocating to CDKN1B and FOS promoter regions and recruiting EP300 resulting in acetylation of histone H4. Involved in regulation of LEF1 transcriptional activity via interaction with DVL1 and/or DVL2 Also involved in regulation of receptors others than GPCRs. Involved in Toll-like receptor and IL-1 receptor signaling through the interaction with TRAF6 which prevents TRAF6 autoubiquitination and oligomerization required for activation of NF-kappa-B and JUN. Binds phosphoinositides. Binds inositol hexakisphosphate (InsP6)

Region 2: 282-309 Region 5: 333-340 Region 4: 376-380 Region 1: 357-382 Region 3: 383-393

Map of ordered and disordered regions







Note: 'Mouse' over a region to see the start and stop residues. Click on a region to see detailed information.


Region 1
Type:Disordered
Name: 
Location:357 - 382
Length:26
Region sequence:

KEEPPHREVPEHETPVDTNLIELDTN

Modification type: Fragment
PDB: 1G4M:A, 1G4R:A
Structural/functional type: Function arises via a disorder to order transition
Functional classes: Molecular assembly
Functional subclasses: Substrate/ligand binding
Detection methods:
  1. X-ray crystallography (292 K; protein (5 or 7.5 ug/ml); NaCl 0.1 M; Tris-HCl (pH 8.5) 20 mM; EDTA 1 mM; DTT 10 mM; Glycerol (5%))

  2. X-ray crystallography (292 K; MgCl2 0.8 M; PEG 1500 (18-20%); Tris-HCl (pH 7.5) 0.1 M)

  3. X-ray crystallography (292 K; BaCl2 0.4 M; PEG 4000 (12-14.5%); Tris-HCl (pH 7.5) 0.1 M)

References:
  1. Han M, Gurevich VV, Vishnivetskiy SA, Sigler PB, Schubert C. "Crystal structure of beta-arrestin at 1.9 A: possible mechanism of receptor binding and membrane Translocation." Structure (Camb). 2001; 9(9): 869-80. PubMed: 11566136

Comments:
The fragment used to determine the crystal structure consisted of residues 1-393.




Region 2
Type:Disordered
Name:Lariat loop
Location:282 - 309
Length:28
Region sequence:

REKRGLALDGKLKHEDTNLASSTLLREG

Modification type: Fragment
PDB: 1G4M:A, 1G4R:A
Structural/functional type: Function arises via a disorder to order transition
Functional classes: Molecular recognition effectors
Functional subclasses: Substrate/ligand binding
Detection methods:
  1. X-ray crystallography (292 K; DTT 10 mM; EDTA 1 mM; Glycerol (5%); NaCl 0.1 M; protein (5 or 7.5 mg/ml); Tris-HCl (pH 8.5) 20 mM)

  2. X-ray crystallography (292 K; MgCl2 0.8 M; PEG 1500 (18-20%); Tris-HCl (pH 7.5) 0.1 M)

  3. X-ray crystallography (292 K; BaCl2 0.4 M; PEG 4000 (12-14.5%); Tris-HCl (pH 7.5) 0.1 M)

References:
  1. Han M, Gurevich VV, Vishnivetskiy SA, Sigler PB, Schubert C. "Crystal structure of beta-arrestin at 1.9 A: possible mechanism of receptor binding and membrane Translocation." Structure (Camb). 2001; 9(9): 869-80. PubMed: 11566136

Comments:
The fragment used to determine the crystal structure consisted of residues 1-393.


Residues 280-310 are the major binding site of autoimmune antibodies found in high levels of some multiple sclerosis patients.




Region 3
Type:Disordered
Name:C tail
Location:383 - 393
Length:11
Region sequence:

DDDIVFEDFAR

Modification type: Fragment
PDB: 1G4M:A, 1G4R:A
Structural/functional type: Function arises via a disorder to order transition
Functional classes: Molecular assembly
Functional subclasses: Substrate/ligand binding
Detection methods:
  1. X-ray crystallography (292 K; DTT 10 mM; EDTA 1 mM; Glycerol (5%); NaCl 0.1 M; protein (5 or 7.5 mg/ml); Tris-HCl (pH 8.5) 20 mM)

  2. X-ray crystallography (292 K; MgCl2 0.8 M; PEG 1500 (18-20%); Tris-HCl (pH 7.5) 0.1 M)

  3. X-ray crystallography (292 K; BaCl2 0.4 M; PEG 4000 (12-14.5%); Tris-HCl (pH 7.5) 0.1 M)

References:
  1. Han M, Gurevich VV, Vishnivetskiy SA, Sigler PB, Schubert C. "Crystal structure of beta-arrestin at 1.9 A: possible mechanism of receptor binding and membrane Translocation." Structure (Camb). 2001; 9(9): 869-80. PubMed: 11566136

Comments:
The fragment used to determine the crystal structure consisted of residues 1-393.




Region 4
Type:Disordered
Name:Clathrin binding box
Location:376 - 380
Length:5
Region sequence:

LIELD

Modification type: Fragment
PDB: 3GC3:A
Structural/functional type: Function arises via a disorder to order transition
Functional classes: Molecular recognition effectors
Functional subclasses: Substrate/ligand binding
Detection methods:
 
References:
  1. Kang DS, Kern RC, Puthenveedu MA, von Zastrow M, Williams JC, Benovic JL. "Structure of an arrestin2/clathrin complex reveals a novel clathrin binding domain that modulates receptor trafficking." J Biol Chem. 2009. PubMed: 19710023

Comments:
The clathrin binding box is present in isoforms 1A and 1B.




Region 5
Type:Disordered
Name: 
Location:333 - 340
Length:8
Region sequence:

GLLGDLAS

Modification type: Fragment
PDB: 3GD1:C
Structural/functional type:  
Functional classes: Molecular recognition effectors
Functional subclasses: Substrate/ligand binding
Detection methods:
 
References:
  1. Kang DS, Kern RC, Puthenveedu MA, von Zastrow M, Williams JC, Benovic JL. "Structure of an arrestin2/clathrin complex reveals a novel clathrin binding domain that modulates receptor trafficking." J Biol Chem. 2009. PubMed: 19710023

Comments:
Region 5 is present only in isoform 1A. This region can mediate arrestin distribution to clathrin coated pits.




Comments


A separate entry may be needed for isoform 1B.


If you have any comments or wish to provide additional references to this protein or its disordered region(s), please click here to e-mail us.


Disprot-footer
Contact us